Amennai Beyeen Joins Rhenman & Partners as a Biopharma Analyst

Amennai Beyeen joins Rhenman & Partners as a biopharma analyst where he will pay close attention to biopharma firms and the creation of novel medications and therapies.

Mr Beyeen will collaborate with each of his five colleagues on the investment team at Rhenman & Partners, who are all situated in the company’s Stockholm headquarters.

Mr Beyeen previously worked at Novartis for 12 years, where he focused on the development and market introduction of novel medications. Prior to that he had earned a doctorate in neuroimmunology from Sweden’s Karolinska Institutet.

The companies co-founder, Henrik Rhenman, explained how they are “very happy to welcome Amennai to Rhenman & Partners. Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”

Mr Beyeen expressed that he is looking forward to starting: “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years. I look forward to joining this competent team and contributing with my experience from the life science sector.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.